To evaluate the effect of dexmedetomidine on patient recovery from anesthesia in gynecologic laparoscopic surgery. A total of 74 patients who underwent gynecological laparoscopic surgery in our hospital between January 2020 and March 2022 were recruited and assigned via random method to receive either 0.6 μg/ kg of saline (observation group) or 0.6 μg/kg of dexmedetomidine (experimental group) before anesthesia induction during gynecologic laparoscopic surgery, with 37 cases in each group. Outcome measures included postoperative indices (recovery time, awakening time, orientation recovery time and extubation time), Ramsay scores, hemodynamic indices (heart rate, mean arterial pressure, pulse oximetry) at different time points and postoperative adverse events. Dexmedetomidine resulted in significantly shorter respiratory recovery time, awakening time, orientation recovery time and extubation time vs. control treatment (p<0.05). The Ramsay scores in the experimental group were significantly higher than those in the observation group (p<0.05) after treatment. Patients receiving dexmedetomidine showed lower heart rate and mean arterial pressure levels and higher pulse oximetry levels at extubation and 15 min after extubation than the controls (p<0.05). The incidence of postoperative adverse reactions in the experimental group was significantly lower than that in the observation group (p<0.05). Dexmedetomidine effectively shortens the recovery time of respiration, awakening time, recovery time of orientation and extubation time in patients undergoing gynecological laparoscopy and maintains the hemodynamic stability of the body without increasing the risk of postoperative adverse events in patients.